Telmisartan alleviates rosiglitazone-induced bone loss in ovariectomized spontaneous hypertensive rats
Authors:
- J.L. JiJJJ.L. Ji
- H. JiHJH. Ji
- X. YuXYX. Yu
- L.J. DingLDL.J. Ding
- K. LiuKLK. Liu
- Y.Q. LiYLY.Q. Li
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (30801424/c180112)
This publication has 34 references indexed in Scilit:
- Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic MiceHypertension, 2009
- Angiotensin II accelerates osteoporosis by activating osteoclastsThe FASEB Journal, 2008
- Thiazolidinediones: effects on insulin resistance and the cardiovascular systemBritish Journal of Pharmacology, 2008
- Rosiglitazone Induces Decreases in Bone Mass and Strength that Are Reminiscent of Aged BoneEndocrinology, 2007
- Thiazolidinedione Therapy Gets ComplicatedDiabetes Care, 2007
- Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fatBone, 2006
- Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist With Selective PPARγ–Modulating ActivityHypertension, 2004
- Defective Fatty Acid Uptake in the Spontaneously Hypertensive Rat Is a Primary Determinant of Altered Glucose Metabolism, Hyperinsulinemia, and Myocardial HypertrophyJournal of Biological Chemistry, 2001
- Quantification of Bone Microarchitecture with the Structure Model IndexComputer Methods in Biomechanics and Biomedical Engineering, 1997
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987